Swiss Neurotechnology Startup Advances Minimally Invasive Brain Surgery with Neuro Access Platform
Why is real-time imaging crucial for neurosurgeons today? Clee Medical SA, a Swiss neurotechnology company, is addressing this critical challenge with its Neuro Access platform. Based in Geneva, Clee Medical is developing ultra-high-resolution real-time imaging technology to enhance the precision and safety of brain surgery. The company has just secured a significant Seed funding round, led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick, alongside existing investors Wyss Center Geneva.
Clee Medical has successfully closed its Seed financing round, marking a pivotal step in the development of its Neuro Access platform. This innovative solution combines OCT imaging with advanced navigation to provide neurosurgeons with real-time, detailed views of brain anatomy during stereotactic procedures. “Neurosurgery still relies heavily on pre-operative imaging, while the reality in the operating room is dynamic and uncertain,” said Matthew Lapinski, Co-Founder and CEO of Clee Medical SA. “This Seed round allows us to bring a new level of real-time visibility into the brain, supporting safer procedures and expanding what minimally invasive neurosurgery can achieve.”
Key Insights at a Glance
- Real-Time Imaging: Neuro Access offers live, detailed views of brain anatomy, enhancing surgical precision.
- Minimally Invasive: The platform fits naturally into existing surgical practices without requiring new techniques.
- Patient Outcomes: The technology aims to improve patient outcomes by reducing the risk of accidental damage.
- Regulatory Steps: Funding will be used to complete clinical testing and regulatory milestones.
Why Real-Time Imaging is Essential in Neurosurgery
Neurosurgery is a high-stakes field where precision is paramount. Surgeons often rely on pre-operative scans, but the brain can shift during surgery, rendering these images less reliable. This discrepancy can lead to critical errors, such as damaging vital structures. Neuro Access addresses this issue by providing real-time, ultra-high-resolution imaging, allowing surgeons to navigate with greater accuracy and confidence. The technology not only enhances patient safety but also expands the capabilities of minimally invasive procedures, making them more effective and less risky. The need for such advancements is urgent, as millions of patients undergo brain surgery each year, and the stakes are only getting higher.
The Regulatory Clock Is Already Running for Neurotechnology
Just as a conductor must keep the orchestra in perfect harmony, Clee Medical must synchronize its development with the stringent regulatory requirements of the medical field. The Seed funding will enable the company to move from the research phase into clinical testing, a crucial step in bringing the Neuro Access platform to market. Like a well-conducted symphony, this process requires precision and coordination. The initial study with human patients and the completion of regulatory steps are essential milestones that will bring real-time brain imaging into the operating room, making it a standard tool for neurosurgeons. This timeline is critical, as the technology’s potential to improve patient outcomes is significant.
Clee Medical Advances Minimally Invasive Neurosurgery
Clee Medical is advancing the frontiers of neurosurgery with its Neuro Access platform. This minimally invasive solution combines OCT imaging with advanced navigation, providing neurosurgeons with real-time, detailed views of brain anatomy. The device is a slender probe, no wider than instruments already used in common brain procedures, ensuring it fits seamlessly into existing surgical practices. “Clee Medical not only holds the promise of improving patient outcomes but also highlights Wyss Geneva’s dedication to bridging the gap between scientific discovery and real-world impact,” said Dr. Erwin Böttinger, CEO of Wyss Geneva.
The technology can identify critical structures, such as blood vessels, before the surgeon reaches them, significantly reducing the risk of accidental damage. This innovation is poised to transform the way brain surgery is performed, making it safer and more precise.
Future Outlook
The future of neurosurgery is rapidly evolving, and Clee Medical is at the forefront of this transformation. The Seed funding will be used to complete clinical testing, regulatory steps, and initial human studies, bringing the Neuro Access platform closer to market readiness. The company’s commitment to advancing minimally invasive neurosurgery is evident, and the potential impact on patient outcomes is substantial. As the technology progresses, it will likely become a standard tool in operating rooms, enhancing the precision and safety of brain procedures.
Conclusion
Clee Medical’s Neuro Access platform represents a significant leap forward in neurosurgery, offering real-time imaging that enhances surgical precision and patient safety. For neurosurgeons and medical institutions, this technology could be a game-changer. How is your institution preparing for the integration of real-time imaging in neurosurgery? Join the conversation in the comments below.
About Clee Medical SA
Clee Medical SA is a Geneva-based medical technology company developing the Neuro Access platform — a minimally invasive neurotechnology solution combining ultra-high-resolution real-time OCT imaging with surgical navigation for precision brain surgery. Clee Medical emerged from cutting-edge neuroscience research at the Wyss Center Geneva in 2024, backed by the continued support of the Wyss venture ecosystem. Founded in 2024, Clee Medical was named one of the Top 100 Swiss Startups in 2025.
About Wyss Center Geneva
Wyss Geneva is an independent, not-for-profit neuro venture builder with strong translational R&D roots, committed to transforming the treatment of neurological and mental health disorders. Based at Campus Biotech in Geneva, the Center drives innovation at the intersection of artificial intelligence, bioengineering, and neuroengineering to restore neural functions and deliver precision therapies. Established in 2014 with the support of Swiss entrepreneur and philanthropist Hansjörg Wyss, the Center collaborates with ventures, clinical and academic institutions, industry partners and investors to push the boundaries of neurotechnology.
Source link: https://www.businesswire.com/
